Related references
Note: Only part of the references are listed.Acquired Immunity to Malaria
Denise L. Doolan et al.
CLINICAL MICROBIOLOGY REVIEWS (2009)
Immunoglobulin G Subclass-Specific Responses against Plasmodium falciparum Merozoite Antigens Are Associated with Control of Parasitemia and Protection from Symptomatic Illness
Danielle I. stanisic et al.
INFECTION AND IMMUNITY (2009)
Morphology and kinetics of the three distinct phases of red blood cell invasion by Plasmodium falciparum merozoites
Paul R. Gilson et al.
INTERNATIONAL JOURNAL FOR PARASITOLOGY (2009)
Insecticide-treated net coverage in Africa: mapping progress in 2000-07
Abdisalan M. Noor et al.
LANCET (2009)
Blood Stage Malaria Vaccine Eliciting High Antigen-Specific Antibody Concentrations Confers No Protection to Young Children in Western Kenya
Bernhards R. Ogutu et al.
PLOS ONE (2009)
Role of the Plasmodium Export Element in Trafficking Parasite Proteins to the Infected Erythrocyte
Justin A. Boddey et al.
TRAFFIC (2009)
Antibody responses to a panel of Plasmodium falciparum malaria blood-stage antigens in relation to clinical disease outcome in Sudan
Nnaemeka C. Iriemenam et al.
VACCINE (2009)
Emerging rules for subunit-based, multiantigenic, multistage chemically synthesized vaccines
Manuel E. Patarroyo et al.
ACCOUNTS OF CHEMICAL RESEARCH (2008)
Exported proteins required for virulence and rigidity of Plasmodium falciparum-infected human erythrocytes
Alexander G. Maier et al.
CELL (2008)
Estimating the burden of global mortality in children aged <5 years by pathogen-specific causes
Salenna R. Elliott et al.
CLINICAL INFECTIOUS DISEASES (2008)
Malaria vaccines: the case for a whole-organism approach
Alberto Pinzon-Charry et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2008)
Various carrier system(s)mediated genetic vaccination strategies against malaria
Rajeev K. Tyagi et al.
EXPERT REVIEW OF VACCINES (2008)
Variation in use of erythrocyte invasion pathways by Plasmodium falciparum mediates evasion of human inhibitory antibodies
Kristina E. M. Persson et al.
JOURNAL OF CLINICAL INVESTIGATION (2008)
Comparison of Biological Activity of Human Anti-Apical Membrane Antigen-1 Antibodies Induced by Natural Infection and Vaccination
Kazutoyo Miura et al.
JOURNAL OF IMMUNOLOGY (2008)
Ex vivo cytokine and memory T cell responses to the 42-kDa fragment of Plasmodium falciparum merozoite surface protein-1 in vaccinated volunteers
Maria Cecilia Huaman et al.
JOURNAL OF IMMUNOLOGY (2008)
Acquisition of invasion-inhibitory antibodies specific for the 19-kDa fragment of merozoite surface protein 1 in a transmigrant population requires multiple infections
E. Elsa Herdiana Murhandarwati et al.
JOURNAL OF INFECTIOUS DISEASES (2008)
A new global malaria eradication strategy
Richard Feachem et al.
LANCET (2008)
Cohort study of the association of antibody levels to AMA1, MSP119, MSP3 and GLURP with protection from clinical malaria in Ghanaian children
Daniel Dodoo et al.
MALARIA JOURNAL (2008)
Malaria research in the post-genomic era
Elizabeth Ann Winzeler
NATURE (2008)
The genome of the simian and human malaria parasite Plasmodium knowlesi
A. Pain et al.
NATURE (2008)
Comparative genomics of the neglected human malaria parasite Plasmodium vivax
Jane M. Carlton et al.
NATURE (2008)
Efficacy of RTS,S/AS01E Vaccine against Malaria in Children 5 to 17 Months of Age
Philip Bejon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Safety and Immunogenicity of RTS,S/AS02D Malaria Vaccine in Infants
Salim Abdulla et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
A Trial of Combination Antimalarial Therapies in Children from Papua New Guinea
Harin A. Karunajeewa et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Phase 1 Study of a Combination AMA1 Blood Stage Malaria Vaccine in Malian Children
Alassane Dicko et al.
PLOS ONE (2008)
Evidence of Blood Stage Efficacy with a Virosomal Malaria Vaccine in a Phase IIa Clinical Trial
Fiona M. Thompson et al.
PLOS ONE (2008)
Safety and Immunogenicity of a Malaria Vaccine, Plasmodium falciparum AMA-1/MSP-1 Chimeric Protein Formulated in Montanide ISA 720 in Healthy Adults
Jinhong Hu et al.
PLOS ONE (2008)
Protection Induced by Plasmodium falciparum MSP142 Is Strain-Specific, Antigen and Adjuvant Dependent, and Correlates with Antibody Responses
Jeffrey A. Lyon et al.
PLOS ONE (2008)
Phase 1 Trial of AMA1-C1/Alhydrogel plus CPG 7909: An Asexual Blood-Stage Vaccine for Plasmodium falciparum Malaria
Gregory E. D. Mullen et al.
PLOS ONE (2008)
What can transgenic parasites tell us about the development of Plasmodium-specific immune responses?
J. Thompson et al.
PARASITE IMMUNOLOGY (2008)
Safety and Immunogenicity of a Recombinant Plasmodium falciparum AMA1 Malaria Vaccine Adjuvanted with Alhydrogel™, Montanide ISA 720 or AS02
Meta Roestenberg et al.
PLOS ONE (2008)
Acquisition of Growth-Inhibitory Antibodies against Blood-Stage Plasmodium falciparum
Fiona J. McCallum et al.
PLOS ONE (2008)
Antibody-Mediated Growth Inhibition of Plasmodium falciparum: Relationship to Age and Protection from Parasitemia in Kenyan Children and Adults
Arlene E. Dent et al.
PLOS ONE (2008)
Naturally acquired Duffy-binding protein-specific binding inhibitory antibodies confer protection from blood-stage Plasmodium vivax infection
Christopher L. King et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Switching Plasmodium falciparum genes on and off for erythrocyte invasion
Alfred Cortes
TRENDS IN PARASITOLOGY (2008)
Apical membrane antigen 1: a malaria vaccine candidate in review
Edmond J. Remarque et al.
TRENDS IN PARASITOLOGY (2008)
Recent insights into humoral and cellular immune responses against malaria
James G. Beeson et al.
TRENDS IN PARASITOLOGY (2008)
A Phase 1 trial of PfCP2.9: An AMA1/MSP1 chimeric recombinant protein vaccine for Plasmodium falciparum malaria
Elissa Malkin et al.
VACCINE (2008)
Production, quality control, stability and pharmacotoxicity of cGMP-produced Plasmodium falciparum AMA1 FVO strain ectodomain expressed in Pichia pastoris
Bart W. Faber et al.
VACCINE (2008)
The limits and intensity of Plasmodium falciparum transmission:: Implications for malaria control and elimination worldwide
Carlos A. Guerra et al.
PLOS MEDICINE (2008)
Humoral responses to Plasmodium falciparum blood-stage antigens and association with incidence of clinical malaria in children living in an area of seasonal malaria transmission in Burkina Faso, West Africa
Issa Nebie et al.
INFECTION AND IMMUNITY (2008)
Cross-species immunity in malaria vaccine development: Two, three, or even four for the price of one?
Bruno Douradinha et al.
INFECTION AND IMMUNITY (2008)
A partially structured region of a largely unstructured protein, Plasmodium falciparum merozoite surface protein 2 (MSP2), forms amyloid-like fibrils
Xiaodong Yang et al.
JOURNAL OF PEPTIDE SCIENCE (2007)
Plasmodium vivax invasion of human erythrocytes inhibited by antibodies directed against the Duffy binding protein
Brian T. Grimberg et al.
PLOS MEDICINE (2007)
Impact of a Plasmodium falciparum AMA1 Vaccine on Antibody Responses in Adult Malians
Alassane Dicko et al.
PLOS ONE (2007)
A Randomized Placebo-Controlled Phase Ia Malaria Vaccine Trial of Two Virosome-Formulated Synthetic Peptides in Healthy Adult Volunteers
Blaise Genton et al.
PLOS ONE (2007)
A novel flow cytometric phagocytosis assay of malaria-infected erythrocytes
Emma Tippett et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2007)
Identification of protein complexes in detergent-resistant membranes of Plasmodium falciparum schizonts
Paul R. Sanders et al.
MOLECULAR AND BIOCHEMICAL PARASITOLOGY (2007)
Structural basis of antigenic escape of a malaria vaccine candidate
Sheetij Dutta et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Plasmodium strain determines dendritic cell function essential for survival from malaria
Michelle N. Wykes et al.
PLOS PATHOGENS (2007)
Viral vector vaccines make memory T cells against malaria
Arturo Reyes-Sandoval et al.
IMMUNOLOGY (2007)
Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malariu-naive adults at the Walter Reed Army Institute of Research
Mark E. Polhemus et al.
VACCINE (2007)
Structure-activity-based design of a synthetic malaria peptide eliciting sporozoite inhibitory antibodies in a virosomal formulation
Shinji L. Okitsu et al.
CHEMISTRY & BIOLOGY (2007)
The importance of human FcγRI in mediating protection to malaria
Richard S. McIntosh et al.
PLOS PATHOGENS (2007)
Structural studies on Plasmodium vivax merozoite surface protein-1
Jeffrey J. Babon et al.
MOLECULAR AND BIOCHEMICAL PARASITOLOGY (2007)
Glutamate-rich protein (GLURP) induces antibodies that inhibit in vitro growth of Plasmodium falciparum in a phase 1 malaria vaccine trial
Cornelus C. Hermsen et al.
VACCINE (2007)
Safety and immtunogenicity of the Plasmodium falciparum merozoite surface protein-3 long synthethic peptide (MSP3-LSP) malaria vaccine in healthy, semi-immune adult males in Burkina Faso, West Africa
Sodiomon B. Sirima et al.
VACCINE (2007)
Phase 1 randomized double-blind safety an immunogenicity trial of Plasmodium falciparum malaria merozoite surface protein FMP1 vaccine, adjuvanted with AS02A, in adults in western Kenya
Jose A. Stoute et al.
VACCINE (2007)
Genome-wide variation and identification of vaccine targets in the Plasmodium falciparum genome
Jianbing Mu et al.
NATURE GENETICS (2007)
Effect of the malaria vaccine Combination B on merozoite surface antigen 2 diversity
Christian Flueck et al.
INFECTION GENETICS AND EVOLUTION (2007)
A case for whole-parasite malaria vaccines
Michelle Wykes et al.
INTERNATIONAL JOURNAL FOR PARASITOLOGY (2007)
Safety and allele-specific immunogenicity of a malaria vaccine in Malian adults: Results of a phase I randomized trial
Mahamadou A. Thera et al.
PLOS CLINICAL TRIALS (2006)
Safety and reactogenicity of an MSP-1 malaria vaccine candidate: A randomized phase Ib dose-escalation trial in Kenyan children
Mark R. Withers et al.
PLOS CLINICAL TRIALS (2006)
A phase 2b randomised trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya
Philip Bejon et al.
PLOS CLINICAL TRIALS (2006)
Preclinical evaluation of a chimeric malaria vaccine candidate in Montanide ISA 720®
Jan A. M. Langermans et al.
HUMAN VACCINES (2006)
Global genetic diversity and evolution of var genes associated with placental and severe childhood malaria
Adama R. Trimnell et al.
MOLECULAR AND BIOCHEMICAL PARASITOLOGY (2006)
Immunity to recombinant Plasmodium falciparum merozoite surface protein 1 (MSP1):: Protection in Aotus nancymai monkeys strongly correlates with anti-MSP1 antibody titer and in vitro parasite-inhibitory activity
Sanjay Singh et al.
INFECTION AND IMMUNITY (2006)
Vaccination against malaria with live parasites
Laurent Renia et al.
EXPERT REVIEW OF VACCINES (2006)
Disguising itself -: insights into Plasmodium falciparum binding and immune evasion from the DBL crystal structure
Dasein P. -G. Howell et al.
MOLECULAR AND BIOCHEMICAL PARASITOLOGY (2006)
Plasmodium falciparum AMA1 binds a rhoptry neck protein homologous to TgRON4, a component of the moving junction in Toxoplasma gondii
David L. Alexander et al.
EUKARYOTIC CELL (2006)
Virulence of malaria is associated with differential expression of Plasmodium falciparum var gene subgroups in a case-control study
M Kaestli et al.
JOURNAL OF INFECTIOUS DISEASES (2006)
High levels of serum antibodies to merozoite surface protein 2 of Plasmodium falciparum are associated with reduced risk of clinical malaria in coastal Kenya
SD Polley et al.
VACCINE (2006)
Development and optimization of high-throughput methods to measure Plasmodium falciparum-specific growth inhibitory antibodies
Kristina E. M. Persson et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2006)
Phase I safety and immunogenicity trial of FMP1/AS02A, a Plasmodium falciparum MSP-1 asexual blood stage vaccine
CF Ockenhouse et al.
VACCINE (2006)
Antigenic differences and conservation among placental Plasmodium falciparum-infected erythrocytes and acquisition of variant-specific and cross-reactive antibodies
JG Beeson et al.
JOURNAL OF INFECTIOUS DISEASES (2006)
Sequence polymorphisms in the receptor-binding domain of Plasmodium falciparum EBA-175:: Implications for malaria vaccine development
A Mamillapalli et al.
MOLECULAR AND BIOCHEMICAL PARASITOLOGY (2006)
Invasion of red blood cells by malaria parasites
AF Cowman et al.
CELL (2006)
Structural basis for Duffy recognition by the malaria parasite Duffy-binding-like domain
SK Singh et al.
NATURE (2006)
Target antigen, age, and duration of antigen exposure independently regulate immunoglobulin G subclass switching in malaria
JE Tongren et al.
INFECTION AND IMMUNITY (2006)
Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children:: single-blind extended follow-up of a randomised controlled trial
PL Alonso et al.
LANCET (2005)
Distinct protein classes including novel merozoite surface antigens in raft-like membranes of Plasmodium falciparum
PR Sanders et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Invasion by P-falciparum merozoites suggests a hierarchy of molecular interactions
Jake Baum et al.
PLOS PATHOGENS (2005)
Phase I malaria vaccine trial with a long synthetic peptide derived from the merozoite surface protein 3 antigen
R Audran et al.
INFECTION AND IMMUNITY (2005)
Plasmodium falciparum variant surface antigen expression patterns during malaria
Peter C. Bull et al.
PLOS PATHOGENS (2005)
Antigenicity, immunogenicity, and protective efficacy of Plasmodium vivax MSP1 Pv200L:: A potential malaria vaccine subunit
A Valderrama-Aguirre et al.
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE (2005)
A malaria vaccine that elicits in humans antibodies able to kill Plasmodium falciparum
P Druilhe et al.
PLOS MEDICINE (2005)
Structure of AMA1 from Plasmodium falciparum reveals a clustering of polymorphisms that surround a conserved hydrophobic pocket
T Bai et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Structural basis for the EBA-175 erythrocyte invasion pathway of the malaria parasite Plasmodium falciparum
NH Tolia et al.
CELL (2005)
Safety and immunogenicty of RTS,S/AS02A candidate malaria vaccine in Gambian children
KA Bojang et al.
VACCINE (2005)
Gene polymorphism of Plasmodium falciparum merozoite surface proteins 4 and 5
HEJ Polson et al.
MOLECULAR AND BIOCHEMICAL PARASITOLOGY (2005)
Phase 1 clinical trial of apical membrane antigen 1:: an asexual blood-stage vaccine for Plasmodium falciparum malaria
EM Malkin et al.
INFECTION AND IMMUNITY (2005)
Cross-reactive surface epitopes on chondroitin sulfate A-adherent Plasmodium falciparum-infected erythrocytes are associated with transcription of var2csa
SR Elliott et al.
INFECTION AND IMMUNITY (2005)
Crystal structure of the malaria vaccine candidate apical membrane antigen 1
JC Pizarro et al.
SCIENCE (2005)
The global distribution of clinical episodes of Plasmodium falciparum malaria
RW Snow et al.
NATURE (2005)
A comprehensive survey of the Plasmodium life cycle by genomic, transcriptomic, and proteomic analyses
N Hall et al.
SCIENCE (2005)
Immunological processes in malaria pathogenesis
L Schofield et al.
NATURE REVIEWS IMMUNOLOGY (2005)
Allelic polymorphisms in apical membrane antigen-1 are responsible for evasion of antibody-mediated inhibition in Plasmodium falciparum
J Healer et al.
MOLECULAR MICROBIOLOGY (2004)
A Plasmodium falciparum GLURP-MSP3 chimeric protein;: expression in Lactococcus lactis, immunogenicity and induction of biologically active antibodies
M Theisen et al.
VACCINE (2004)
A co-ligand complex anchors Plasmodium falciparum merozoites to the erythrocyte invasion receptor band 3
XR Li et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
A Plasmodium falciparum candidate vaccine based on a six-antigen polyprotein encoded by recombinant poxviruses
E Prieur et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Medicinal application of long synthetic peptide technology
G Corradin et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2004)
Identification of a conserved region of Plasmodium falciparum MSP3 targeted by biologically active antibodies to improve vaccine design
S Singh et al.
JOURNAL OF INFECTIOUS DISEASES (2004)
Human antibodies to recombinant protein constructs of Plasmodium falciparum Apical Membrane Antigen 1 (AMA1) and their associations with protection from malaria
SD Polley et al.
VACCINE (2004)
Evidence that invasion-inhibitory antibodies specific for the 19-kDa fragment of merozoite surface protein-1 (MSP-119) can play a protective role against blood-stage Plasmodium falciparum infection in individuals in a malaria endemic area of Africa
CC John et al.
JOURNAL OF IMMUNOLOGY (2004)
Antigenic drift in the ligand domain of Plasmodium vivax Duffy binding protein confers resistance to inhibitory antibodies
KM VanBuskirk et al.
JOURNAL OF INFECTIOUS DISEASES (2004)
Association between protection, against clinical malaria and antibodies to merozoite surface antigens in an area of hyperendernicity in myanmar: Complementarity between responses to merozoite surface protein 3 and the 220-kilodalton glutamate-rich protein
S Soe et al.
INFECTION AND IMMUNITY (2004)
Evidence for the involvement of VAR2CSA in pregnancy-associated malaria
A Salanti et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2004)
A randomised, double-blind, controlled vaccine efficacy trial of DNA/MVA ME-TRAP against malaria infection in Gambian adults
VS Moorthy et al.
PLOS MEDICINE (2004)
Progress in DNA-based heterologous prime-boost immunization strategies for malaria
AC Moore et al.
IMMUNOLOGICAL REVIEWS (2004)
Strain-specific humoral response to a polymorphic malaria vaccine
C Flück et al.
INFECTION AND IMMUNITY (2004)
Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children:: randomised controlled trial
PL Alonso et al.
LANCET (2004)
Fusion of two malaria vaccine candidate antigens enhances product yield, immunogenicity, and antibody-mediated inhibition of parasite growth in vitro
WQ Pan et al.
JOURNAL OF IMMUNOLOGY (2004)
Plasmodium falciparum associated with severe childhood malaria preferentially expresses PfEMP1 encoded by group A var genes
ATR Jensen et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2004)
Inhibition of 19-kDa C-terminal region of merozoite surface protein-1-specific antibody responses in neonatal pups by maternally derived 19-kDa C-terminal region of merozoite surface protein-1-specific antibodies but not whole parasite-specific antibodies
DI Stanisic et al.
JOURNAL OF IMMUNOLOGY (2004)
Safety and immunogenicity of a three-component blood-stage malaria vaccine (MSP1, MSP2, RESA) against Plasmodium falciparum in Papua New Guinean children
B Genton et al.
VACCINE (2003)
Prime-boost strategies for malaria vaccine development
SJ Dunachie et al.
JOURNAL OF EXPERIMENTAL BIOLOGY (2003)
Utilization of genomic sequence information to develop malaria vaccines
DL Doolan et al.
JOURNAL OF EXPERIMENTAL BIOLOGY (2003)
DNA immunization with the cysteine-rich interdomain region 1 of the Plasmodium falciparum variant antigen elicits limited cross-reactive antibody responses
DI Baruch et al.
INFECTION AND IMMUNITY (2003)
Induction of parasite growth-inhibitory antibodies by a virosomal formulation of a peptidomimetic of loop I from domain III of Plasmodium falciparum apical membrane antigen 1
MS Mueller et al.
INFECTION AND IMMUNITY (2003)
Glycophorin C is the receptor for the Plasmodium falciparum erythrocyte binding ligand PfEBP-2 (baebl)
CA Lobo et al.
BLOOD (2003)
Crystal structure of a fab complex formed with PfMSP1-19, the C-terminal fragment of merozoite surface protein 1 from Plasmodium falciparum:: A malaria vaccine candidate
JC Pizarro et al.
JOURNAL OF MOLECULAR BIOLOGY (2003)
Band 3 is a host receptor binding merozoite surface protein 1 during the Plasmodium falciparum invasion of erythrocytes
VK Goel et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
A novel erythrocyte binding antigen-175 paralogue from Plasmodium falciparum defines a new trypsin-resistant receptor on human erythrocytes
TW Gilberger et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Repeat sequences in block 2 of Plasmodium falciparum merozoite surface protein 1 are targets of antibodies associated with protection from malaria
SD Polley et al.
INFECTION AND IMMUNITY (2003)
Geographical structure of diversity and differences between symptomatic and asymptomatic infections for Plasmodium falciparum vaccine candidate AMA1
A Cortes et al.
INFECTION AND IMMUNITY (2003)
Plasmodium falciparum erythrocyte invasion through glycophorin C and selection for Gerbich negativity in human populations
AG Maier et al.
NATURE MEDICINE (2003)
Biochemical and immunological characterization of bacterially expressed and refolded Plasmodium falciparum 42-kilodalton C-terminal merozoite surface protein 1
S Singh et al.
INFECTION AND IMMUNITY (2003)
Vaccination of monkeys with recombinant Plasmodium falciparum apical membrane antigen 1 confers protection against blood-stage malaria
AW Stowers et al.
INFECTION AND IMMUNITY (2002)
Immunization with a combination of merozoite surface proteins 4/5 and 1 enhances protection against lethal challenge with Plasmodium yoelii
L Kedzierski et al.
INFECTION AND IMMUNITY (2002)
In vitro studies with recombinant Plasmodium falciparum apical membrane antigen 1 (AMA1):: Production and activity of an AMA1 vaccine and generation of a multiallelic response
MC Kennedy et al.
INFECTION AND IMMUNITY (2002)
The genome sequence of the malaria mosquito Anopheles gambiae
RA Holt et al.
SCIENCE (2002)
Excess Polymorphisms in genes for membrane proteins in Plasmodium falciparum
SK Volkman et al.
SCIENCE (2002)
Genome sequence and comparative analysis of the model rodent malaria parasite Plasmodium yoelii yoelii
JM Carlton et al.
NATURE (2002)
A proteomic view of the Plasmodium falciparum life cycle
L Florens et al.
NATURE (2002)
Genome sequence of the human malaria parasite Plasmodium falciparum
MJ Gardner et al.
NATURE (2002)
Immunity to malaria after administration of ultra-low doses of red cells infected with Plasmodium falciparum
DJ Pombo et al.
LANCET (2002)
Synthetic GPI as a candidate anti-toxic vaccine in a model of malaria
L Schofield et al.
NATURE (2002)
Bacterially expressed and refolded receptor binding domain of Plasmodium falciparum EBA-175 elicits invasion inhibitory antibodies
KC Pandey et al.
MOLECULAR AND BIOCHEMICAL PARASITOLOGY (2002)
High-level expression of the malaria blood-stage vaccine candidate Plasmodium falciparum apical membrane antigen 1 and induction of antibodies that inhibit erythrocyte invasion
CHM Kocken et al.
INFECTION AND IMMUNITY (2002)
Purification, characterization, and immunogenicity of the refolded ectodomain of the Plasmodium falciparum apical membrane antigen 1 expressed in Escherichia coli
S Dutta et al.
INFECTION AND IMMUNITY (2002)
Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites
SL Hoffman et al.
JOURNAL OF INFECTIOUS DISEASES (2002)
The central role played by peptides in the immune response and the design of peptide-based vaccines against infectious diseases and cancer
DC Jackson et al.
CURRENT DRUG TARGETS (2002)
Immunization of Aotus monkeys with a functional domain of the Plasmodium falciparum variant antigen induces protection against a lethal parasite line
DI Baruch et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea
B Genton et al.
JOURNAL OF INFECTIOUS DISEASES (2002)
Pathogenesis of Plasmodium falciparum malaria:: the roles of parasite adhesion and antigenic variation
JG Beeson et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2002)
Truncation of merozoite surface protein 3 disrupts its trafficking and that of acidic-basic repeat protein to the surface of Plasmodium falciparum merozoites
KE Mills et al.
MOLECULAR MICROBIOLOGY (2002)
Efficacy of RTS,S/ASO2 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia:: a randomised trial
KA Bojang et al.
LANCET (2001)
Naturally acquired antibody responses to Plasmodium falciparum merozoite surface protein 4 in a population living in an area of endemicity in Vietnam
L Wang et al.
INFECTION AND IMMUNITY (2001)
A novel ligand from Plasmodium falciparum that binds to a sialic acid-containing receptor on the surface of human erythrocytes
JK Thompson et al.
MOLECULAR MICROBIOLOGY (2001)
Antibodies against merozoite surface protein (MSP)-119 are a major component of the invasion-inhibitory response in individuals immune to malaria
RA O'Donnell et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2001)
DNA-based vaccines against malaria: status and promise of the multi-stage malaria DNA vaccine operation
DL Doolan et al.
INTERNATIONAL JOURNAL FOR PARASITOLOGY (2001)
Characterization of a Plasmodium falciparum erythrocyte-binding protein paralogous to EBA-175
DCG Mayer et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Inhibitory and blocking monoclonal antibody epitopes on merozoite surface protein 1 of the malaria parasite Plasmodium falciparum
C Uthaipibull et al.
JOURNAL OF MOLECULAR BIOLOGY (2001)
Polymorphism in the gene encoding the apical membrane antigen-1 (AMA-1) of Plasmodium falciparum.: X.: Asembo Bay Cohort Project
AA Escalante et al.
MOLECULAR AND BIOCHEMICAL PARASITOLOGY (2001)
Initial sequencing and analysis of the human genome
ES Lander et al.
NATURE (2001)
Protection of Aotus monkeys by Plasmodium falciparum EBA-175 region II DNA prime-protein boost immunization regimen
TR Jones et al.
JOURNAL OF INFECTIOUS DISEASES (2001)
Conservation and heterogeneity of the glutamate-rich protein (GLURP) among field isolates and laboratory lines of Plasmodium faliparum
K de Stricker et al.
MOLECULAR AND BIOCHEMICAL PARASITOLOGY (2000)
Analysis of human antibodies to erythrocyte binding antigen 175 of Plasmodium falciparum
DMN Okenu et al.
INFECTION AND IMMUNITY (2000)
Immunization with recombinant Plasmodium yoelii merozoite surface protein 4/5 protects mice against lethal challenge
L Kedzierski et al.
INFECTION AND IMMUNITY (2000)
Repeated infection of Aotus monkeys with Plasmodium falciparum induces protection against subsequent challenge with homologous and heterologous strains of parasite
TR Jones et al.
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE (2000)
Safety and immunogenicity of a three-component blood-stage malaria vaccine in adults living in an endemic area of Papua New Guinea
B Genton et al.
VACCINE (2000)
Effect of vaccination with 3 recombinant asexual-stage malaria antigens on initial growth rates of Plasmodium falciparum in non-immune volunteers
G Lawrence et al.
VACCINE (2000)
Antibodies against the Plasmodium falciparum receptor binding domain of EBA-175 block invasion pathways that do not involve sialic acids
DL Narum et al.
INFECTION AND IMMUNITY (2000)
Naturally acquired antibodies to the glutamate-rich protein are associated with protection against Plasmodium falciparum malaria
D Dodoo et al.
JOURNAL OF INFECTIOUS DISEASES (2000)
Share Paper
